Moderna, Inc. (NASDAQ:MRNA) Stock Position Lessened by Russell Investments Group Ltd.

Russell Investments Group Ltd. decreased its holdings in Moderna, Inc. (NASDAQ:MRNA – Get Rating) by 13.1% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 88,569 shares of the company’s stock after selling 13,317 shares during the quarter. Russell Investments Group Ltd.’s holdings in Moderna were worth $15,327,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of MRNA. Confluence Wealth Services Inc. acquired a new stake in shares of Moderna in the fourth quarter valued at $25,000. Standard Family Office LLC acquired a new stake in shares of Moderna in the fourth quarter valued at $25,000. Lake Point Wealth Management acquired a new stake in shares of Moderna in the fourth quarter valued at $27,000. IFS Advisors LLC acquired a new stake in shares of Moderna in the fourth quarter valued at $27,000. Finally, Bivin & Associates Inc. acquired a new stake in shares of Moderna in the fourth quarter valued at $29,000. Institutional investors own 61.20% of the company’s stock.

Moderna Stock Performance

Shares of MRNA opened at $194.18 on Friday. The company’s 50 day moving average price is $151.55 and its 200 day moving average price is $152.84. Moderna, Inc. has a 52 week low of $115.61 and a 52 week high of $497.49. The company has a market capitalization of $77.24 billion, a PE ratio of 5.71, a PEG ratio of 0.91 and a beta of 1.61. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.56 and a current ratio of 1.77.

Moderna (NASDAQ:MRNA – Get Rating) last announced its quarterly earnings data on Wednesday, August 3rd. The company reported $5.24 EPS for the quarter, beating analysts’ consensus estimates of $4.73 by $0.51. Moderna had a net margin of 64.77% and a return on equity of 121.86%. The firm had revenue of $4.73 billion for the quarter, compared to the consensus estimate of $3.95 billion. During the same period in the previous year, the firm posted $6.46 earnings per share. The firm’s revenue was up 8.7% on a year-over-year basis. Research analysts expect that Moderna, Inc. will post 27.16 EPS for the current fiscal year.

Insider Activity at Moderna

In other Moderna news, CEO Stephane Bancel sold 9,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 11th. The shares were sold at an average price of $127.13, for a total value of $1,144,170.00. Following the completion of the sale, the chief executive officer now directly owns 5,395,535 shares of the company’s stock, valued at $685,934,364.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Moderna news, President Stephen Hoge sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 13th. The shares were sold at an average price of $168.88, for a total value of $844,400.00. Following the completion of the sale, the president now directly owns 1,624,231 shares of the company’s stock, valued at $274,300,131.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Stephane Bancel sold 9,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 11th. The stock was sold at an average price of $127.13, for a total transaction of $1,144,170.00. Following the completion of the sale, the chief executive officer now directly owns 5,395,535 shares of the company’s stock, valued at $685,934,364.55. The disclosure for this sale can be found here. Over the last three months, insiders have sold 554,029 shares of company stock valued at $82,263,545. Corporate insiders own 17.30% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on MRNA. SVB Leerink upped their price objective on Moderna from $70.00 to $77.00 and gave the company an “underperform” rating in a report on Monday. Morgan Stanley reduced their target price on Moderna from $199.00 to $197.00 and set an “equal weight” rating for the company in a report on Thursday. Finally, Piper Sandler reduced their target price on Moderna from $348.00 to $214.00 and set an “overweight” rating for the company in a report on Tuesday, May 17th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, Moderna currently has an average rating of “Hold” and a consensus target price of $226.92.

Moderna Company Profile

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.